May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
The Retinal Tolerance to Bevacizumab in Co-Application With a Recombinant Tissue Plasminogen Activator
Author Affiliations & Notes
  • M. Luke
    Department of Ophthalmology I, Tuebingen, Tuebingen, Germany
  • K. Januschowski
    Department of Ophthalmology I, Tuebingen, Tuebingen, Germany
  • J. Beutel
    Department of Ophthalmology I, Tuebingen, Tuebingen, Germany
  • K. U. Bartz-Schmidt
    Department of Ophthalmology I, Tuebingen, Tuebingen, Germany
  • P. Szurman
    Department of Ophthalmology I, Tuebingen, Tuebingen, Germany
  • Tuebingen Bevacizumab Study Group
    Department of Ophthalmology I, Tuebingen, Tuebingen, Germany
  • Footnotes
    Commercial Relationships M. Luke, None; K. Januschowski, None; J. Beutel, None; K.U. Bartz-Schmidt, None; P. Szurman, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 77. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Luke, K. Januschowski, J. Beutel, K. U. Bartz-Schmidt, P. Szurman, Tuebingen Bevacizumab Study Group; The Retinal Tolerance to Bevacizumab in Co-Application With a Recombinant Tissue Plasminogen Activator. Invest. Ophthalmol. Vis. Sci. 2007;48(13):77.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To investigate the retinal toxicity of bevacizumab in co-application with rt-PA, a commercially available recombinant tissue plasminogen activator (rt-PA), and to facilitate a new therapeutic concept in the treatment of massive subretinal haemorrhage caused by neovascular age-related macular degeneration (AMD).

Methods:: Isolated bovine retinas were perfused with an oxygen preincubated nutrient solution. The electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes. Bevacizumab (0.25mg/ml) and rt-PA (20µg/ml) was added to the nutrient solution for 45 min. Thereafter, the retina was reperfused for 60 min with normal nutrient solution. Similarly, the effects of rt-PA (20µg/ml and 60µg/ml) were investigated on the a- and b-wave amplitude. The percentage of a- and b-wave reduction during the application and at the washout was calculated.

Results:: During the application of different concentrations of rt-PA (20µg/ml and 60µg/ml) as well as for the co-application with bevacizumab (0.25mg/ml, 20µg/ml rt-PA) no significant reduction of the a- and b-wave amplitude was observed. During the washout, the ERG-amplitudes remained unchanged.

Conclusions:: The present study suggests that a subretinal injection of 20µg/ml rt-PA in co-application with bevacizumab (0.25mg/ml) for the treatment of massive subretinal haemorrhage seems possible.

Keywords: retina • electroretinography: non-clinical • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×